Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Banco de datos
Tipo de estudio
Tipo del documento
Intervalo de año de publicación
1.
J Lipid Res ; 54(4): 1066-76, 2013 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-23322884

RESUMEN

Micrometric membrane lipid segregation is controversial. We addressed this issue in attached erythrocytes and found that fluorescent boron dipyrromethene (BODIPY) analogs of glycosphingolipids (GSLs) [glucosylceramide (BODIPY-GlcCer) and monosialotetrahexosylganglioside (GM1BODIPY)], sphingomyelin (BODIPY-SM), and phosphatidylcholine (BODIPY-PC inserted into the plasma membrane spontaneously gathered into distinct submicrometric domains. GM1BODIPY domains colocalized with endogenous GM1 labeled by cholera toxin. All BODIPY-lipid domains disappeared upon erythrocyte stretching, indicating control by membrane tension. Minor cholesterol depletion suppressed BODIPY-SM and BODIPY-PC but preserved BODIPY-GlcCer domains. Each type of domain exchanged constituents but assumed fixed positions, suggesting self-clustering and anchorage to spectrin. Domains showed differential association with 4.1R versus ankyrin complexes upon antibody patching. BODIPY-lipid domains also responded differentially to uncoupling at 4.1R complexes [protein kinase C (PKC) activation] and ankyrin complexes (in spherocytosis, a membrane fragility disease). These data point to micrometric compartmentation of polar BODIPY-lipids modulated by membrane tension, cholesterol, and differential association to the two nonredundant membrane:spectrin anchorage complexes. Micrometric compartmentation might play a role in erythrocyte membrane deformability and fragility.


Asunto(s)
Eritrocitos/metabolismo , Lípidos de la Membrana/química , Western Blotting , Compuestos de Boro/química , Membrana Celular/efectos de los fármacos , Membrana Celular/metabolismo , Células Cultivadas , Colesterol/química , Cromatografía en Capa Delgada , Eritrocitos/efectos de los fármacos , Eritrocitos/ultraestructura , Glicoesfingolípidos/química , Compuestos Heterocíclicos con 3 Anillos/química , Humanos , Microscopía Electrónica de Rastreo , Fosfatidilcolinas/química , Esfingomielinas/química , beta-Ciclodextrinas/farmacología
2.
J Infect Dis ; 204 Suppl 3: S957-67, 2011 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-21987776

RESUMEN

Virus entry into host cells is the first step of infection and a crucial determinant of pathogenicity. Here we show that Ebola virus-like particles (EBOV-VLPs) composed of the glycoprotein GP(1,2) and the matrix protein VP40 use macropinocytosis and clathrin-mediated endocytosis to enter cells. EBOV-VLPs applied to host cells induced actin-driven ruffling and enhanced FITC-dextran uptake, which indicated macropinocytosis as the main entry mechanism. This was further supported by inhibition of entry through inhibitors of actin polymerization (latrunculin A), Na(+)/H(+)-exchanger (EIPA), and PI3-kinase (wortmannin). A fraction of EBOV-VLPs, however, colocalized with clathrin heavy chain (CHC), and VLP uptake was reduced by CHC small interfering RNA transfection and expression of the dominant negative dynamin II-K44A mutant. In contrast, we found no evidence that EBOV-VLPs enter cells via caveolae. This work identifies macropinocytosis as the major, and clathrin-dependent endocytosis as an alternative, entry route for EBOV particles. Therefore, EBOV seems to utilize different entry pathways depending on both cell type and virus particle size.


Asunto(s)
Clatrina/fisiología , Ebolavirus/fisiología , Endocitosis/fisiología , Células Epiteliales/virología , Internalización del Virus , Actinas/fisiología , Amilorida/análogos & derivados , Amilorida/farmacología , Androstadienos/farmacología , Animales , Compuestos Bicíclicos Heterocíclicos con Puentes/farmacología , Caveolina 1/metabolismo , Línea Celular , Células Epiteliales/metabolismo , Silenciador del Gen , Interacciones Huésped-Patógeno , Humanos , ARN Interferente Pequeño , Transducción de Señal , Tiazolidinas/farmacología , Replicación Viral , Wortmanina
3.
Mol Cell Biochem ; 339(1-2): 63-77, 2010 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-20058056

RESUMEN

It has been shown that changes in spectrin distribution in early apoptosis preceded changes in membrane asymmetry and phosphatidylserine (PS) exposure. PKCtheta was associated with spectrin during these changes, suggesting a possible role of spectrin/PKCtheta aggregation in regulation of early apoptotic events. Here we dissect this hypothesis using Jurkat T and HL60 cell lines as model systems. Immunofluorescent analysis of alphaIIbetaII spectrin arrangement in Jurkat T and HL60 cell lines revealed the redistribution of spectrin and PKCtheta into a polar aggregate in early apoptosis induced by fludarabine/mitoxantrone/dexamethasone (FND). The appearance of an alphaIIbetaII spectrin fraction that was insoluble in a non-ionic detergent (1% Triton X-100) was observed concomitantly with spectrin aggregation. The changes were observed within 2 h after cell exposure to FND, and preceded PS exposure. The changes seem to be restricted to spectrin and not to other cytoskeletal proteins such as actin or vimentin. In studies of the mechanism of these changes, we found that (i) neither changes in apoptosis regulatory genes (e.g., Bcl-2 family proteins) nor changes in cytoskeleton-associated proteins were detected in gene expression profiling of HL60 cells after the first hour of FND treatment, (ii) caspase-3, -7, -8, and -10 had minor involvement in the early apoptotic rearrangement of spectrin/PKCtheta, and (iii) spectrin aggregation was shown to be partially dependent on PKCtheta activity. Our results indicate that spectrin/PKCtheta aggregate formation is related to an early stage in drug-induced apoptosis and possibly may be regulated by PKCtheta activity. These findings indicate that spectrin/PKCtheta aggregation could be considered as a hallmark of early apoptosis and presents the potential to become a useful diagnostic tool for monitoring efficiency of chemotherapy as early as 24 h after treatment.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/farmacología , Apoptosis/efectos de los fármacos , Isoenzimas/metabolismo , Proteína Quinasa C/metabolismo , Espectrina/metabolismo , Actinas/metabolismo , Western Blotting , Caspasa 3/metabolismo , Inhibidores de Caspasas , Citoesqueleto/efectos de los fármacos , Citoesqueleto/metabolismo , Dexametasona/administración & dosificación , Citometría de Flujo , Técnica del Anticuerpo Fluorescente , Células HL-60 , Humanos , Células Jurkat , Mitoxantrona/administración & dosificación , Octoxinol , Proteína Quinasa C-theta , Multimerización de Proteína , ARN Mensajero/genética , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Vidarabina/administración & dosificación , Vidarabina/análogos & derivados , Vimentina/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA